Accurate diagnosis and molecular characterization are fundamental to modern cancer management. This session explores developments in pathology, molecular diagnostics, biomarker discovery, liquid biopsy, minimal residual disease detection, and laboratory technologies that support cancer classification, prognosis, monitoring, and therapeutic decision-making.
Abstract Scope and Participation
Abstracts may cover histopathology, molecular pathology, cancer biomarkers, companion diagnostics, liquid biopsy, circulating tumor DNA, minimal residual disease, molecular testing, diagnostic platforms, and emerging laboratory methods. Pathologists, laboratory scientists, oncologists, molecular biologists, diagnostic researchers, and industry professionals are welcome.
Minimal residual disease (MRD) can persist in cancer patients even after potential cure, resulting in cancer recurrence and contributing to the low five-year survival rate of cancer patients.…
Background: The lecture will introduce the audience to commonly utilized techniques for Cytology of malignant fluids including cytospin, cell block and immunohistochemistry. The advantages and…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Cancer Pathology, Molecular Diagnostics & Biomarkers work, reviewed by the scientific committee.
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Cancer Pathology, Molecular Diagnostics & Biomarkers research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Cancer Pathology, Molecular Diagnostics & Biomarkers track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Cancer Pathology, Molecular Diagnostics & Biomarkers. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Cancer researchers and clinicians, educators and students with an interest in Cancer Pathology, Molecular Diagnostics & Biomarkers are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. CIOC 2027 is a hybrid conference — attend the Cancer Pathology, Molecular Diagnostics & Biomarkers track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
